BPC-157 is a synthetic peptide derived from a protein in human gastric juice; preclinical research shows it may speed gut lining repair, cut GI inflammation, and protect against NSAID-induced damage — available at TelosRX subject to medical approval by a licensed provider; not FDA-approved.
Your gut is one of the few tissues in the body that turns over rapidly — the intestinal lining replaces itself roughly every five to seven days. When that process breaks down, from chronic NSAID use, inflammatory bowel disease, or other insults, the repair machinery needs support. BPC-157 has drawn attention in preclinical research precisely because it appears to accelerate that machinery.
What follows is a plain-language breakdown of what BPC-157 is, how it acts in the GI tract, and what the research actually shows — including the significant caveat that human clinical trial data remains limited.
What Is BPC-157 and Where Does It Come From?
BPC stands for Body Protection Compound. BPC-157 is a synthetic analog of a peptide fragment isolated from human gastric juice — the secretion your stomach uses to begin protein digestion. The full-length protein it's derived from is present naturally in the gut and appears to play a role in mucosal protection.
The synthetic version is a 15-amino-acid chain. Unlike many peptides, BPC-157 demonstrates stability in gastric conditions — meaning it resists degradation in stomach acid, which makes oral delivery feasible in animal models.
Key characteristics of BPC-157:
- Length: 15 amino acids (pentadecapeptide)
- Origin: derived from the amino acid sequence of BPC, a protein in human gastric secretion
- Stability: resistant to gastric acid degradation in preclinical models
- Administration routes studied: oral, subcutaneous injection, intramuscular injection
- Regulatory status: not FDA-approved; classified as a research compound; compounded preparations require provider-issued prescription
BPC-157 also has a broader research profile beyond gut health — including tendon repair, nerve healing, and anti-inflammatory effects. See best peptides for tendon repair for that angle.
How BPC-157 Works in the Gut: Mechanisms
Preclinical research has identified several pathways through which BPC-157 appears to act on gastrointestinal tissue:
| Mechanism | What It Does | Evidence Level |
|---|---|---|
| Angiogenesis promotion | Stimulates new blood vessel formation via VEGF upregulation, delivering oxygen and nutrients to damaged tissue | Preclinical (animal models) |
| Nitric oxide modulation | Acts as an NO promoter/stabilizer depending on context; supports vascular function and tissue protection | Preclinical |
| Cytokine regulation | Reduces pro-inflammatory cytokines TNF-α, IL-6, and IFN-γ; shifts macrophage phenotype toward reparative M2 | Preclinical (PMC12446177) |
| Intestinal permeability stabilization | Protects tight junctions in the gut lining; studied in NSAID-induced intestinal damage models | Preclinical (Current Pharm Des, 2020) |
| Growth factor receptor interaction | Interacts with pathways controlling cellular migration and proliferation needed for mucosal repair | Preclinical |
The anti-inflammatory mechanism — particularly the shift from pro-inflammatory M1 macrophages to reparative M2 macrophages — is especially relevant for chronic gut conditions where inflammation drives ongoing damage to the mucosal lining.
What Research Shows for Gut Lining Repair
BPC-157's origins as a gastric-derived compound mean the earliest and most extensive animal research focused on GI healing. Studies published in Life Sciences and the Journal of Physiology and Pharmacology going back to the 1990s showed BPC-157 reduced gastric and duodenal lesions caused by:
- Restraint stress
- Cysteamine (used to create ulcer models)
- 96% ethanol exposure
In these rat models, BPC-157 outperformed H2 receptor antagonists (a class of common antacid medications) in reducing mucosal lesion size and accelerating repair.
More recent work has focused on its protective role in the intestinal lining beyond the stomach. A 2020 study in Current Pharmaceutical Design (Park et al., PMID 32445447) found BPC-157 rescued intestinal cells from NSAID-induced cytotoxicity by stabilizing intestinal permeability — essentially, it helped prevent the gut wall from becoming leaky in the presence of commonly used over-the-counter pain medications.
This matters because NSAID-induced gut damage is underrecognized. Long-term NSAID users frequently develop small intestinal injury that doesn't show up on standard endoscopy but causes chronic GI symptoms.
BPC-157 and Inflammatory Bowel Research
A narrative review published in PMC (2025, PMC12446177) confirmed that BPC-157 significantly decreases TNF-α, IL-6, and IFN-γ — three cytokines central to the inflammatory cascade in conditions like Crohn's disease and ulcerative colitis.
The same review noted BPC-157's ability to promote resolution of inflammation by shifting macrophage activity from the M1 phenotype (pro-inflammatory, tissue-damaging) to the M2 phenotype (reparative, anti-fibrotic). This macrophage polarization is a major target of current IBD drug research.
It's important to be clear about what this means and what it doesn't: these findings are from animal models and in vitro cell studies. BPC-157 has not been studied in randomized controlled trials for inflammatory bowel disease in humans. The research provides mechanistic evidence and biological plausibility, not clinical proof.
For another well-studied gut health peptide, see our guide to KPV peptide for gut health and IBD research.
BPC-157 for NSAID-Induced GI Damage: A Closer Look
NSAIDs — ibuprofen, naproxen, aspirin in higher doses — are among the most common causes of GI mucosal injury worldwide. They work by blocking prostaglandin synthesis, which also removes the prostaglandin-dependent protection of the stomach and intestinal lining.
BPC-157's cytoprotective mechanism in NSAID damage models appears to work independently of the prostaglandin pathway — which is notable because it suggests BPC-157 could potentially protect the gut lining through a mechanism that NSAIDs don't directly block.
In animal studies, BPC-157 reduced intestinal permeability and preserved mucosal integrity even when NSAIDs were administered at doses sufficient to cause GI ulceration in controls. These results are preclinical and have not been replicated in human subjects.
Delivery Routes: Oral vs. Injectable for Gut Applications
One practical consideration for GI applications: oral BPC-157 may be the most logical delivery route for gut-targeted effects, since it contacts the mucosa directly.
- Oral administration: Studied in animal models; BPC-157's gastric acid stability makes it a functional option for upper and lower GI delivery. Direct mucosal contact may be relevant for gut-specific effects.
- Subcutaneous injection: Systemic exposure; studied for systemic anti-inflammatory and healing effects.
- Intramuscular injection: Similar to subcutaneous; more often used in musculoskeletal research models.
The route selected in any compounded preparation should be determined by a licensed provider reviewing your specific health situation. BPC-157 is not FDA-approved and compounded preparations must be issued under a provider-issued prescription following evaluation.
For a comprehensive overview of BPC-157 research across applications, see our BPC-157 patient guide — and for how it compares to other repair peptides, see TB-500 tissue repair research.
Interested in a peptide evaluation? TelosRX's asynchronous clinical team reviews your intake online — no scheduled calls, no waiting rooms — and a licensed provider determines if a prescription is appropriate. Subject to medical approval by a licensed provider.
Safety Profile and What Isn't Known
In preclinical animal research, BPC-157 has a strong safety profile. Studies note:
- No observed toxicity in standard rodent dosing studies across multiple administration routes
- No evidence of carcinogenicity in preclinical models
- No significant adverse effects on hormonal, renal, or hepatic parameters in animal studies
What remains unknown:
- Human pharmacokinetics, bioavailability, and optimal dosing — no large-scale human trials have been completed
- Long-term effects in humans
- Drug interactions in clinical populations
BPC-157 is a research compound. Using it outside of proper medical supervision introduces risks that the preclinical data cannot fully characterize. All TelosRX evaluations are reviewed by a licensed provider before any prescription is issued.
Frequently Asked Questions
What is BPC-157 used for in the gut?
In preclinical research, BPC-157 is studied for gastric ulcer healing, intestinal lining repair, reduction of GI inflammation, and protection against NSAID-induced gut damage. It is not FDA-approved for any of these applications, and human clinical trial data is limited. All use requires a provider-issued prescription following medical evaluation.
Can BPC-157 heal leaky gut?
Preclinical research shows BPC-157 helps stabilize intestinal permeability — what's colloquially called "leaky gut" — in animal models of NSAID-induced damage and stress-induced mucosal injury. These findings have not been replicated in human randomized controlled trials. Compounded BPC-157 is not FDA-approved.
Is BPC-157 safe for the gut?
Animal studies report no significant toxicity from BPC-157 at doses used in research. Human safety data from controlled trials is absent. The safety profile in humans is not established. Any use should be under licensed provider supervision — TelosRX evaluations are reviewed asynchronously by a licensed provider before a prescription is issued.
What's the difference between oral and injectable BPC-157 for gut health?
Oral administration delivers BPC-157 directly to the mucosal lining of the stomach and intestines, which may be the most relevant route for GI-targeted effects. Injectable (subcutaneous or intramuscular) administration provides systemic exposure. BPC-157's gastric acid stability makes oral delivery functional in preclinical models. The optimal route for any individual is determined by a licensed provider.
Does BPC-157 help with IBD or Crohn's disease?
BPC-157 has been studied in animal models of intestinal inflammation and shows anti-inflammatory effects through TNF-α, IL-6, and macrophage polarization pathways — all relevant to IBD. Human trials have not been conducted for this indication. It's not FDA-approved for IBD treatment.
How does BPC-157 compare to other gut peptides like KPV?
BPC-157 and KPV target overlapping but distinct mechanisms. BPC-157 emphasizes mucosal repair and permeability stabilization; KPV (a melanocortin receptor-targeting tripeptide) is studied more specifically for its anti-inflammatory effects in IBD models. See our KPV gut health guide for a detailed breakdown.
Where can I get BPC-157 evaluated by a provider?
TelosRX offers asynchronous telehealth evaluations for compounded peptides including BPC-157, subject to medical approval by a licensed provider. You complete an online intake; the clinical team reviews it and a licensed provider determines if a compounded prescription is appropriate. Not FDA-approved. Visit telosrx.com to start.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.